🆕 UBC TI #BestEvidence Webinar recording!
"GLP-1 RA and SGLT2i in type 2 diabetes"
Speaker: The TI's @guillaume-grenet.bsky.social
👉 View recording: youtu.be/JUCIfScMqGY
#MedEd #CME #diabetes #CVD
"GLP-1 RA and SGLT2i in type 2 diabetes"
Speaker: The TI's @guillaume-grenet.bsky.social
👉 View recording: youtu.be/JUCIfScMqGY
#MedEd #CME #diabetes #CVD
Dr. Guillaume Grenet: GLP-1 RA and SGLT2i in type 2 diabetes
YouTube video by Therapeutics Initiative
youtu.be
February 13, 2026 at 10:38 PM
🆕 UBC TI #BestEvidence Webinar recording!
"GLP-1 RA and SGLT2i in type 2 diabetes"
Speaker: The TI's @guillaume-grenet.bsky.social
👉 View recording: youtu.be/JUCIfScMqGY
#MedEd #CME #diabetes #CVD
"GLP-1 RA and SGLT2i in type 2 diabetes"
Speaker: The TI's @guillaume-grenet.bsky.social
👉 View recording: youtu.be/JUCIfScMqGY
#MedEd #CME #diabetes #CVD
Another real world parse of NAION risk from a VA new user cohort. The incidence rate of NAION was 123 per 100 000 person-years among semaglutide initiators and 67 per 100 000 person-years among SGLT2i #T2D jamanetwork.com/journals/jam...
New-Onset Nonarteritic Anterior Ischemic Optic Neuropathy and Initiators of Semaglutide in US Veterans With Type 2 Diabetes
This observational study emulates a target trial evaluating the risk of NAION associated with initiation of semaglutide, compared with a sodium-glucose cotransporter-2 inhibitor as second-line therapy...
jamanetwork.com
February 13, 2026 at 11:49 AM
Another real world parse of NAION risk from a VA new user cohort. The incidence rate of NAION was 123 per 100 000 person-years among semaglutide initiators and 67 per 100 000 person-years among SGLT2i #T2D jamanetwork.com/journals/jam...
The latest ASN Kidney Translation Podcast episode covers advances in kidney transplantation: an SGLT2i trial in kidney transplant recipients (CJASN), delivery outcomes after kidney transplantation (JASN), and strategies and policies for living donation (Kidney360). Tune in: kidney.pub/KTPOD022026
February 12, 2026 at 5:01 PM
The latest ASN Kidney Translation Podcast episode covers advances in kidney transplantation: an SGLT2i trial in kidney transplant recipients (CJASN), delivery outcomes after kidney transplantation (JASN), and strategies and policies for living donation (Kidney360). Tune in: kidney.pub/KTPOD022026
Initiation of semaglutide in US veterans with type 2 #Diabetes was linked to a two-fold increased risk of nonarteritic anterior ischemic optic neuropathy compared with SGLT2 inhibitor initiation, though absolute risk was low. ja.ma/4riwx4X
February 12, 2026 at 4:30 PM
Initiation of semaglutide in US veterans with type 2 #Diabetes was linked to a two-fold increased risk of nonarteritic anterior ischemic optic neuropathy compared with SGLT2 inhibitor initiation, though absolute risk was low. ja.ma/4riwx4X
ข้อห้ามสำคัญ * ห้ามใช้ ARBs 2 ชนิด พร้อมกัน -> เสี่ยงไตพัง + โพแทสเซียมสูง ⚠️ ยาเสริมที่ช่วยได้ (แต่ไม่ใช่เพื่อความดันล้วนๆ) * SGLT2i (เช่น Dapagliflozin, Empagliflozin, หรือ Glucagon like peptide-1) / GLP1-RA (เช่น Semaglutide, Liraglutide) *
February 11, 2026 at 8:52 PM
ข้อห้ามสำคัญ * ห้ามใช้ ARBs 2 ชนิด พร้อมกัน -> เสี่ยงไตพัง + โพแทสเซียมสูง ⚠️ ยาเสริมที่ช่วยได้ (แต่ไม่ใช่เพื่อความดันล้วนๆ) * SGLT2i (เช่น Dapagliflozin, Empagliflozin, หรือ Glucagon like peptide-1) / GLP1-RA (เช่น Semaglutide, Liraglutide) *
🩺 Nephrology — Jan 2025
• Gene-edited pig kidneys reveal complex immune responses
• eGFR and family history refine CKD progression risk
• SGLT2i and RNA therapies shift treatment strategies
pir.sh/0D3aPkJdlx
#Nephrology #Kidneydisease #CKD
• Gene-edited pig kidneys reveal complex immune responses
• eGFR and family history refine CKD progression risk
• SGLT2i and RNA therapies shift treatment strategies
pir.sh/0D3aPkJdlx
#Nephrology #Kidneydisease #CKD
Nephrology Research Summary January 2026 - Summarized Science
Summary of key Nephrology publications highlighting major findings, clinical relevance, and emerging research trends.
pir.sh
February 11, 2026 at 8:35 PM
🩺 Nephrology — Jan 2025
• Gene-edited pig kidneys reveal complex immune responses
• eGFR and family history refine CKD progression risk
• SGLT2i and RNA therapies shift treatment strategies
pir.sh/0D3aPkJdlx
#Nephrology #Kidneydisease #CKD
• Gene-edited pig kidneys reveal complex immune responses
• eGFR and family history refine CKD progression risk
• SGLT2i and RNA therapies shift treatment strategies
pir.sh/0D3aPkJdlx
#Nephrology #Kidneydisease #CKD
SGLT2i use associated with lower ULT, NSAID, high-dose glucocorticoid and diuretic use among gout patients, along with fewer flares. Implications for improving gout & cardiometabolic comorbidity care.
Read here ➡️ doi.org/10.2337/dc25-1713
Read here ➡️ doi.org/10.2337/dc25-1713
February 11, 2026 at 6:30 PM
SGLT2i use associated with lower ULT, NSAID, high-dose glucocorticoid and diuretic use among gout patients, along with fewer flares. Implications for improving gout & cardiometabolic comorbidity care.
Read here ➡️ doi.org/10.2337/dc25-1713
Read here ➡️ doi.org/10.2337/dc25-1713
🕕 TODAY (Feb 11 @ Noon Pacific) 🕕
UBC TI #BestEvidence Webinar:
"GLP-1 RA and SGLT2i in type 2 diabetes"
🔉 Speaker: The TI's @guillaume-grenet.bsky.social
👉 Register now: www.ti.ubc.ca/2026/02/03/g...
#MedEd #CME #diabetes #CVD
UBC TI #BestEvidence Webinar:
"GLP-1 RA and SGLT2i in type 2 diabetes"
🔉 Speaker: The TI's @guillaume-grenet.bsky.social
👉 Register now: www.ti.ubc.ca/2026/02/03/g...
#MedEd #CME #diabetes #CVD
February 11, 2026 at 5:39 PM
🕕 TODAY (Feb 11 @ Noon Pacific) 🕕
UBC TI #BestEvidence Webinar:
"GLP-1 RA and SGLT2i in type 2 diabetes"
🔉 Speaker: The TI's @guillaume-grenet.bsky.social
👉 Register now: www.ti.ubc.ca/2026/02/03/g...
#MedEd #CME #diabetes #CVD
UBC TI #BestEvidence Webinar:
"GLP-1 RA and SGLT2i in type 2 diabetes"
🔉 Speaker: The TI's @guillaume-grenet.bsky.social
👉 Register now: www.ti.ubc.ca/2026/02/03/g...
#MedEd #CME #diabetes #CVD
T3f
Safety deserves emphasis.
INFINITI adds high-quality RCT data showing short-term SGLT2i use is feasible and well tolerated in stable KTRs.
#NephJC
Safety deserves emphasis.
INFINITI adds high-quality RCT data showing short-term SGLT2i use is feasible and well tolerated in stable KTRs.
#NephJC
February 11, 2026 at 2:47 AM
T3f
Safety deserves emphasis.
INFINITI adds high-quality RCT data showing short-term SGLT2i use is feasible and well tolerated in stable KTRs.
#NephJC
Safety deserves emphasis.
INFINITI adds high-quality RCT data showing short-term SGLT2i use is feasible and well tolerated in stable KTRs.
#NephJC
T3e
Despite small MAP reductions, there was no improvement in arterial stiffness, SVR, or sympathetic tone.
This suggests transplant-specific vascular and tubular physiology may blunt traditional SGLT2i BP mechanisms.
Perhaps a longer study may have shown different results?⚠️
#NephJC
Despite small MAP reductions, there was no improvement in arterial stiffness, SVR, or sympathetic tone.
This suggests transplant-specific vascular and tubular physiology may blunt traditional SGLT2i BP mechanisms.
Perhaps a longer study may have shown different results?⚠️
#NephJC
February 11, 2026 at 2:46 AM
T3e
Despite small MAP reductions, there was no improvement in arterial stiffness, SVR, or sympathetic tone.
This suggests transplant-specific vascular and tubular physiology may blunt traditional SGLT2i BP mechanisms.
Perhaps a longer study may have shown different results?⚠️
#NephJC
Despite small MAP reductions, there was no improvement in arterial stiffness, SVR, or sympathetic tone.
This suggests transplant-specific vascular and tubular physiology may blunt traditional SGLT2i BP mechanisms.
Perhaps a longer study may have shown different results?⚠️
#NephJC
T3d
👉 Strong glucosuria without natriuresis.
This challenges the classic SGLT2i narrative.
Possible explanations:
• Calcineurin-inhibitor–mediated sodium retention
• Rapid distal sodium reabsorption
• Altered tubular signaling in denervated grafts
#NephJC
👉 Strong glucosuria without natriuresis.
This challenges the classic SGLT2i narrative.
Possible explanations:
• Calcineurin-inhibitor–mediated sodium retention
• Rapid distal sodium reabsorption
• Altered tubular signaling in denervated grafts
#NephJC
February 11, 2026 at 2:45 AM
T3d
👉 Strong glucosuria without natriuresis.
This challenges the classic SGLT2i narrative.
Possible explanations:
• Calcineurin-inhibitor–mediated sodium retention
• Rapid distal sodium reabsorption
• Altered tubular signaling in denervated grafts
#NephJC
👉 Strong glucosuria without natriuresis.
This challenges the classic SGLT2i narrative.
Possible explanations:
• Calcineurin-inhibitor–mediated sodium retention
• Rapid distal sodium reabsorption
• Altered tubular signaling in denervated grafts
#NephJC
T3c
Notably, this occurred without meaningful albuminuria reduction, aligning with growing evidence that SGLT2i benefits go beyond proteinuria.
Were you surprised there wasn’t lowering (of already low) albuminuria?
#NephJC
Notably, this occurred without meaningful albuminuria reduction, aligning with growing evidence that SGLT2i benefits go beyond proteinuria.
Were you surprised there wasn’t lowering (of already low) albuminuria?
#NephJC
February 11, 2026 at 2:44 AM
T3c
Notably, this occurred without meaningful albuminuria reduction, aligning with growing evidence that SGLT2i benefits go beyond proteinuria.
Were you surprised there wasn’t lowering (of already low) albuminuria?
#NephJC
Notably, this occurred without meaningful albuminuria reduction, aligning with growing evidence that SGLT2i benefits go beyond proteinuria.
Were you surprised there wasn’t lowering (of already low) albuminuria?
#NephJC
T3b
📉The preserved acute GFR dip strongly suggests that intraglomerular pressure unloading still occurs in transplanted kidneys. The magnitude of the dip mirrors non-transplant SGLT2i trials — reinforcing that this is likely a hemodynamic, not toxic, effect.
#NephJC
📉The preserved acute GFR dip strongly suggests that intraglomerular pressure unloading still occurs in transplanted kidneys. The magnitude of the dip mirrors non-transplant SGLT2i trials — reinforcing that this is likely a hemodynamic, not toxic, effect.
#NephJC
February 11, 2026 at 2:43 AM
T3b
📉The preserved acute GFR dip strongly suggests that intraglomerular pressure unloading still occurs in transplanted kidneys. The magnitude of the dip mirrors non-transplant SGLT2i trials — reinforcing that this is likely a hemodynamic, not toxic, effect.
#NephJC
📉The preserved acute GFR dip strongly suggests that intraglomerular pressure unloading still occurs in transplanted kidneys. The magnitude of the dip mirrors non-transplant SGLT2i trials — reinforcing that this is likely a hemodynamic, not toxic, effect.
#NephJC
T2g
Proteinuria
At baseline, participants had low-grade proteinuria -UACR ~2–3 mg/mmol- very low
After SGLT2i → NO significant reduction in UACR at 1 or 12 weeks
UACR and 24-hour urine protein excretion remained unchanged across timepoints, despite the clear mGFR dip. #NephJC
Proteinuria
At baseline, participants had low-grade proteinuria -UACR ~2–3 mg/mmol- very low
After SGLT2i → NO significant reduction in UACR at 1 or 12 weeks
UACR and 24-hour urine protein excretion remained unchanged across timepoints, despite the clear mGFR dip. #NephJC
February 11, 2026 at 2:38 AM
T2g
Proteinuria
At baseline, participants had low-grade proteinuria -UACR ~2–3 mg/mmol- very low
After SGLT2i → NO significant reduction in UACR at 1 or 12 weeks
UACR and 24-hour urine protein excretion remained unchanged across timepoints, despite the clear mGFR dip. #NephJC
Proteinuria
At baseline, participants had low-grade proteinuria -UACR ~2–3 mg/mmol- very low
After SGLT2i → NO significant reduction in UACR at 1 or 12 weeks
UACR and 24-hour urine protein excretion remained unchanged across timepoints, despite the clear mGFR dip. #NephJC
T2f
Creatinine-based eGFR showed directionally similar changes, closely mirroring the early hemodynamic dip seen in native-kidney SGLT2i trials.
Crucially, this GFR dip was not accompanied by harm:
❌ No excess AKI
❌ No biochemical instability
❌ No signal for acute rejection
#NephJC
Creatinine-based eGFR showed directionally similar changes, closely mirroring the early hemodynamic dip seen in native-kidney SGLT2i trials.
Crucially, this GFR dip was not accompanied by harm:
❌ No excess AKI
❌ No biochemical instability
❌ No signal for acute rejection
#NephJC
February 11, 2026 at 2:37 AM
T2f
Creatinine-based eGFR showed directionally similar changes, closely mirroring the early hemodynamic dip seen in native-kidney SGLT2i trials.
Crucially, this GFR dip was not accompanied by harm:
❌ No excess AKI
❌ No biochemical instability
❌ No signal for acute rejection
#NephJC
Creatinine-based eGFR showed directionally similar changes, closely mirroring the early hemodynamic dip seen in native-kidney SGLT2i trials.
Crucially, this GFR dip was not accompanied by harm:
❌ No excess AKI
❌ No biochemical instability
❌ No signal for acute rejection
#NephJC
T1h
Tubular sodium handling was studied using lithium clearance, allowing segment-specific assessment of proximal vs distal sodium handling, moving beyond crude natriuresis and directly testing classic SGLT2i mechanisms. #NephJC
Tubular sodium handling was studied using lithium clearance, allowing segment-specific assessment of proximal vs distal sodium handling, moving beyond crude natriuresis and directly testing classic SGLT2i mechanisms. #NephJC
February 11, 2026 at 2:25 AM
T1h
Tubular sodium handling was studied using lithium clearance, allowing segment-specific assessment of proximal vs distal sodium handling, moving beyond crude natriuresis and directly testing classic SGLT2i mechanisms. #NephJC
Tubular sodium handling was studied using lithium clearance, allowing segment-specific assessment of proximal vs distal sodium handling, moving beyond crude natriuresis and directly testing classic SGLT2i mechanisms. #NephJC
T0g
However, kidney transplant recipients have been excluded from all major SGLT2i outcome trials—creating a major evidence gap. For better (overly cautious) or worse, we have limited safety and efficacy data for renal transplant patients. #NephJC
However, kidney transplant recipients have been excluded from all major SGLT2i outcome trials—creating a major evidence gap. For better (overly cautious) or worse, we have limited safety and efficacy data for renal transplant patients. #NephJC
February 11, 2026 at 2:13 AM
T0g
However, kidney transplant recipients have been excluded from all major SGLT2i outcome trials—creating a major evidence gap. For better (overly cautious) or worse, we have limited safety and efficacy data for renal transplant patients. #NephJC
However, kidney transplant recipients have been excluded from all major SGLT2i outcome trials—creating a major evidence gap. For better (overly cautious) or worse, we have limited safety and efficacy data for renal transplant patients. #NephJC
⏰30 min before the #NephJC chat
There has been limited research on SGLT2i in renal transplant recipients till date, and this is the compilation of currently available data. #NephJC
Are you pumped to know how and how well #Flozins work in transplanted patients?
Let's deep dive in a few minutes!
There has been limited research on SGLT2i in renal transplant recipients till date, and this is the compilation of currently available data. #NephJC
Are you pumped to know how and how well #Flozins work in transplanted patients?
Let's deep dive in a few minutes!
February 11, 2026 at 1:30 AM
⏰2 hours until #NephJC chat
SGLT2i has transformed the world of nephrology, with sustained effects on multiple hard end-points. Do their benefits transcend to transplant patients too? Let’s discuss #flozination in Transplant recipients today, 9PM EST in the #NephJC chat.
1/2
SGLT2i has transformed the world of nephrology, with sustained effects on multiple hard end-points. Do their benefits transcend to transplant patients too? Let’s discuss #flozination in Transplant recipients today, 9PM EST in the #NephJC chat.
1/2
February 11, 2026 at 12:00 AM
⏰2 hours until #NephJC chat
SGLT2i has transformed the world of nephrology, with sustained effects on multiple hard end-points. Do their benefits transcend to transplant patients too? Let’s discuss #flozination in Transplant recipients today, 9PM EST in the #NephJC chat.
1/2
SGLT2i has transformed the world of nephrology, with sustained effects on multiple hard end-points. Do their benefits transcend to transplant patients too? Let’s discuss #flozination in Transplant recipients today, 9PM EST in the #NephJC chat.
1/2
Glad to have contributed to this study, which has a very relevant clinical point: the BP lowering effect of SGLT2i of 4-5 mmHg is independent of renal function #nephsky #sglt2i
The Effect of SGLT2 Inhibitors aka #Flozins on Blood Pressure in Relation to Baseline Kidney Function: A Systematic Literature Review and Data Analysis
🔗 academic.oup.com/ajh/article-... 🔒
🔗 academic.oup.com/ajh/article-... 🔒
The Effect of SGLT2 Inhibitors on Blood Pressure in Relation to Baseline Kidney Function: A Systematic Literature Review and Data Analysis
AbstractBACKGROUND. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce both systolic blood pressure (SBP) and diastolic blood pressure (DBP). The gl
academic.oup.com
February 10, 2026 at 8:06 PM
brought to you by big microalbumin
(though seriously, what's the angle? SGLT2i? Dapa price gonna be crashing soon)
(though seriously, what's the angle? SGLT2i? Dapa price gonna be crashing soon)
February 10, 2026 at 12:54 AM
brought to you by big microalbumin
(though seriously, what's the angle? SGLT2i? Dapa price gonna be crashing soon)
(though seriously, what's the angle? SGLT2i? Dapa price gonna be crashing soon)
🚨UBC TI #BestEvidence Webinar
"GLP-1 RA and SGLT2i in type 2 diabetes"
Speaker: The TI's @GrenetGuillaume
👉 Register now: www.ti.ubc.ca/2026/02/03/g...
#MedEd #CME #diabetes #CVD
"GLP-1 RA and SGLT2i in type 2 diabetes"
Speaker: The TI's @GrenetGuillaume
👉 Register now: www.ti.ubc.ca/2026/02/03/g...
#MedEd #CME #diabetes #CVD
February 9, 2026 at 6:50 PM
🚨UBC TI #BestEvidence Webinar
"GLP-1 RA and SGLT2i in type 2 diabetes"
Speaker: The TI's @GrenetGuillaume
👉 Register now: www.ti.ubc.ca/2026/02/03/g...
#MedEd #CME #diabetes #CVD
"GLP-1 RA and SGLT2i in type 2 diabetes"
Speaker: The TI's @GrenetGuillaume
👉 Register now: www.ti.ubc.ca/2026/02/03/g...
#MedEd #CME #diabetes #CVD
Here is the VA for the INFINITI study of SGLT2i in transplant patients by @glomerican.bsky.social #NephSky #Flozins #Flozination
www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract
www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract
INFINITI: The Visual Abstract — NephJC
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in...
www.nephjc.com
February 9, 2026 at 12:40 PM
Here is the VA for the INFINITI study of SGLT2i in transplant patients by @glomerican.bsky.social #NephSky #Flozins #Flozination
www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract
www.nephjc.com/news/2026/2/8/infiniti-the-visual-abstract
Hey #NephSky
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant
To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients — NephJC
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
www.nephjc.com
February 8, 2026 at 11:25 PM
Hey #NephSky
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant
2/10/26 at 9 pm EST we'll discuss
#Flozinating into the Future & Beyond...
SGLT2i in kidney transplant recipients.
What's the latest evidence of risk/benefit?
Do #Flozins act mechanistically the same in de-innervated kidneys?
Come chat.
www.nephjc.com/news/inifinti-flozins-transplant